October 2, 2023 11:24 AM EDT

Rocket’s gene therapy gets a PDUFA date; SAB Biotherapeutics’ $130M; Acurx to move to PhIII

ENDPOINTS

Plus, more news from Amicus Therapeutics, Mogrify, and Clade Therapeutics.

Rocket gets a March date with FDA: The FDA has until March 31 to decide whether to approve Rocket Pharmaceuticals’ gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), which is a rare white blood cell disorder that can result in severe infections. Life expectancy is short, and some babies do not survive past infancy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Rocket’s gene therapy gets a PDUFA date; SAB Biotherapeutics’ $130M; Acurx to move to PhIII

ENDPOINTS

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Rock­et’s gene ther­a­py gets a PDU­FA date; SAB Bio­ther­a­peu­tics’ $130M; Acurx to move to PhI­II

ENDPOINTS

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Rocket’s gene therapy gets a PDUFA date; SAB Biotherapeutics’ $130M; Acurx to move to PhIII

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients